PDCD5 negatively regulates autoimmunity by upregulating FOXP3+ regulatory T cells and suppressing Th17 and Th1 responses

Journal of Autoimmunity

Volumn 47, Issue , 2013, Pages 34-44

  Xiao, Juan ^a,b   Liu, Chen ^a   Li, Ge ^a,b   Peng, Saihui ^a,b   Hu, Jia ^a,b   Qu, Liujing ^a,b   Lv, Ping ^a,b   Zhang, Yu ^a   Ma, Dalong ^a,b   Chen, Yingyu ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Experimental autoimmune encephalomyelitis; FOXP3; PDCD5; Regulatory T cells

Indexed keywords

MEMBRANE PROTEIN; PROGRAMMED CELL DEATH 5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACETYLATION; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CELL POLARITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOMODULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PATHOGENICITY; POLARIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE;

EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FOXP3; PDCD5; REGULATORY T CELLS;

ACETYLATION; ANIMALS; ANTIGENS, CD4; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEK293 CELLS; HISTONE ACETYLTRANSFERASES; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84888202996     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.08.002     Document Type: Article

References (53)

1. Miyara M., Gorochov G., Ehrenstein M., Musset L., Sakaguchi S., Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011, 10(12):744-755.
2. Sakaguchi S., Wing K., Miyara M. Regulatory T cells-a brief history and perspective. Eur J Immunol 2007, 37(Suppl.1):S116-S123.
3. Zheng Y., Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8:457-462.
4. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007, 8:277-284.
5. + T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
6. Rudensky A.Y. Regulatory T cells and Foxp3. Immunol Rev 2011, 241:260-268.
7. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
8. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
9. + T regulatory cells. Nat Immunol 2003, 4:337-342.
10. Beier U.H., Akimova T., Liu Y., Wang L., Hancock W.W. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr Opin Immunol 2011, 23:670-678.
11. Samanta A., Li B., Song X., Bembas K., Zhang G., Katsumata M., et al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci U S A 2008, 105:14023-14027.
12. Li B., Greene M.I. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007, 6:1432-1436.
13. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
14. Xiao Y., Li B., Zhou Z., Hancock W.W., Zhang H., Greene M.I. Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr Opin Immunol 2010, 22:583-591.
15. Li B., Samanta A., Song X., Iacono K.T., Bembas K., Tao R., et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci U S A 2007, 104:4571-4576.
16. van Loosdregt J., Vercoulen Y., Guichelaar T., Gent Y.Y., Beekman J.M., van Beekum O., et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010, 115:965-974.
17. de Zoeten E.F., Wang L., Sai H., Dillmann W.H., Hancock W.W. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010, 138:583-594.
18. Saouaf S.J., Li B., Zhang G., Shen Y., Furuuchi N., Hancock W.W., et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009, 87:99-104.
19. Liu H., Wang Y., Zhang Y., Song Q., Di C., Chen G., et al. TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun 1999, 254:203-210.
20. Han X.R., Sun Y., Bai X.Z. The anti-tumor role and mechanism of integrated andtruncated PDCD5 proteins in osteosarcoma cells. Cell Signal 2012, 24:1713-1721.
21. Zhuge C., Chang Y., Li Y., Chen Y., Lei J. PDCD5-regulated cell fate decision after ultraviolet-irradiation-induced DNA damage. Biophys J 2011, 101:2582-2591.
22. Wang Y., Li X., Wang L., Ding P., Zhang Y., Han W., et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. JCell Sci 2004, 117:1525-1532.
23. Chen Y., Sun R., Han W., Zhang Y., Song Q., Di C., et al. Nuclear translocation of PDCD5 (TFAR19): an early signal for apoptosis?. FEBS Lett 2001, 509:191-196.
24. Spinola M., Meyer P., Kammerer S., Falvella F.S., Boettger M.B., Hoyal C.R., et al. Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. JClin Oncol 2006, 24:1672-1678.
25. Yang Y.H., Zhao M., Li W.M., Lu Y.Y., Chen Y.Y., Kang B. Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells. Apoptosis 2006, 11:993-1001.
26. Ruan G.R., Qin Y.Z., Chen S.S., Li J.L., Ma X., Chang Y., et al. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk Res 2006, 30:1159-1165.
27. Ma X., Ruan G., Wang Y., Li Q., Zhu P., Qin Y.Z., et al. Two single-nucleotide polymorphisms with linkage disequilibrium in the human programmed cell death 5 gene 5' regulatory region affect promoter activity and the susceptibility of chronic myelogenous leukemia in Chinese population. Clin Cancer Res 2005, 11:8592-8599.
28. Du Y.J., Xiong L., Lou Y., Tan W.L., Zheng S.B. Reduced expression of programmed cell death 5 protein in tissue of human prostate cancer. Chin Med Sci J 2009, 24:241-245.
29. Chen C., Zhou H., Xu L., Liu X., Liu Z., Ma D., et al. Prognostic significance of downregulated expression of programmed cell death 5 in chondrosarcoma. JSurg Oncol 2010, 102:838-843.
30. Zhang X., Wang X., Song X., Wei Z., Zhou C., Zhu F., et al. Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas. Oncol Rep 2011, 25:353-358.
31. Xie M., Niu J.H., Chang Y., Qian Q.J., Wu H.P., Li L.F., et al. Anovel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. Apoptosis 2009, 14:1086-1094.
32. Chen C., Zhou H., Xu L., Xu D., Wang Y., Zhang Y., et al. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy invitro and invivo. Apoptosis 2010, 15:805-813.
33. Shi L., Song Q., Zhang Y., Lou Y., Wang Y., Tian L., et al. Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells. Biochem Biophys Res Commun 2010, 396:224-230.
34. Xu L., Chen Y., Song Q., Xu D., Wang Y., Ma D. PDCD5 interacts with Tip60 and functions as a cooperator in acetyltransferase activity and DNA damage-induced apoptosis. Neoplasia 2009, 11:345-354.
35. Xu L., Hu J., Zhao Y., Xiao J., Wang Y., Ma D., et al. PDCD5 interacts with p53 and functions as a positive regulator in the p53 pathway. Apoptosis 2012, 17:1235-1245.
36. Yao H., Feng Y., Zhou T., Wang J., Wang Z.X. NMR studies of the interaction between human programmed cell death 5 and human p53. Biochemistry 2012, 51:2684-2693.
37. Li X., Huang J.P., Ding J. Apoptosis and expression of PDCD5 and Caspase-3 in renal tissues of children with lupus nephritis. Zhonghua Er Ke Za Zhi 2005, 43:517-520.
38. Cheng A.X., Lou S.Q., Zhou H.W., Wang Y., Ma D.L. Expression of PDCD5, a novel apoptosis related protein, in human osteoarthritic cartilage. Acta Pharmacol Sin 2004, 25:685-690.
39. Yi C., Ma C., Xie Z., Zhang G., Song W., Zhou X., et al. Down-regulation of programmed cell death 5 by insulin-like growth factor 1 in osteoarthritis chondrocytes. Int Orthop 2013, 37:937-943.
40. Wang N., Lu H.S., Guan Z.P., Sun T.Z., Chen Y.Y., Ruan G.R., et al. Involvement of PDCD5 in the regulation of apoptosis in fibroblast-like synoviocytes of rheumatoid arthritis. Apoptosis 2007, 12:1433-1441.
41. Chen Y., Zou Z., Xu A., Liu Y., Pan H., Jin L. Serum programmed cell death protein 5 (PDCD5) levels is upregulated in liver diseases. JImmunoassay Immunochem 2013, 34:294-304.
42. Liu H.L., Tian Q., Hong T.P., Liu G.H., Pan H., Wang H.N., et al. Serum level of programmed cell death 5 protein levels in patients with sepsis. Beijing Da Xue Xue Bao 2013, 45:238-241.
43. Diao X.L., Zhu H., He B., Pan H., Wu R., Gai X.Y. Expression and significance of programmed cell death 5 in patients of bronchial asthma. Zhonghua Yi Xue Za Zhi 2012, 92:1392-1395.
44. Wang J., Guan Z., Ge Z. Plasma and synovial fluid programmed cell death 5 (PDCD5) levels are inversely associated with TNF-α and disease activity in patients with rheumatoid arthritis. Biomarkers 2013, 18:155-159.
45. Wang J.F., Guan Z.P., Zhang S.L., Pei Z., Chen Y.Y., Pan H. Programmed cell death 5 correlates with disease activity and interleukin-17 in serum and synovial fluid of rheumatoid arthritis patients. Chin Med J (Engl) 2013, 126:296-299.
46. Zhang P., Zhao M., Liang G., Yin G., Huang D., Su F., et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. JAutoimmun 2013, 41:17-24.
47. Chen L.N., Wang Y., Ma D.L., Chen Y.Y. Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression. Apoptosis 2006, 11:101-111.
48. Legube G., Linares L.K., Tyteca S., Caron C., Scheffner M., Chevillard-Briet M., et al. Role of the histone acetyl transferase Tip60 in the p53 pathway. JBiol Chem 2004, 279:44825-44833.
49. Salvi M., Xu D., Chen Y., Cabrelle A., Sarno S., Pinna L.A. Programmed cell death protein 5 (PDCD5) is phosphorylated by CK2 invitro and in 293T cells. Biochem Biophys Res Commun 2009, 387:606-610.
50. Gavin M.A., Torgerson T.R., Houston E., DeRoos P., Ho W.Y., Stray-Pedersen A., et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006, 103:6659-6664.
51. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
52. Allan S.E., Alstad A.N., Merindol N., Crellin N.K., Amendola M., Bacchetta R., et al. Generation of potent and stable human CD4+ T regulatory cells byactivation-independent expression of FOXP3. Mol Ther 2008, 16:194-202.
53. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.